Paroles d’experts: interview of URODELIA and David Sayag, veterinarian specialised in oncology
We would like to thank you for your support during this very special period.
Research continues, our teams are always mobilized. By following this link, you will find an interview of Mrs Rouquet, president of URODELIA and Dr Sayag, vet oncologist at CHV Advetia (France), about the use of this immunotherapy in his department (from 3min07 with English subtitles):
Activities restarted in compliance with government measures following spread of Coronavirus
Dear customers, dears partners,
URODELIA staff is pleased to announce the resumption of all its activities, in compliance with the health measures recommended to limit the spread of the Coronavirus COVID-19.
Thank you for your understanding in this particular situation and for all the support you have given us on a daily basis.
Please continue to take care of yourself and your loved ones.
Government measures to limit the spread of the Coronavirus
Dear customers, dears partners,
Due to the crisis related to the spread of the Coronavirus COVID-19 and in accordance with French government guidelines, URODELIA staff will not be able to insure shipments of APAVAC kits – until further notice.
However, we remain available for all requests by email (firstname.lastname@example.org).
We will keep you informed of the evolution of this situation. Thank you for your understanding in this particular situation. In the meantime, please take care of yourself and your loved ones.
The Monegasque Biennial of Oncology welcomed Urodelia during an oral presentation
February 2020. At the end of January 2020, Nicole Rouquet, President of Urodelia, presented the personalized immunotherapy technology developed by Urodelia at the Monegasque Biennial of Oncology. A presentation which was attended by many participants!
Le journal des entreprises devotes an article to Urodelia
November 2019. Urodelia is the subject of an article in the Journal des Entreprises (n-° 387).Nicole Rouquet, President of Urodelia, is interviewed by Fleur Olagnier about the cancer treatment developed by Urodelia, its concept and perspectives
The journal “La Semaine Vétérinaire”
October 2019. The journal “la semaine vétérinaire » October 11, 2019” reports on the latest results of the dog cancer treatment studies developed by Urodelia, an article written by Tanit Halfon.
The journal “La Depeche Vétérinaire”
September 2019. The monthly technical supplement to the « Depeche veterinaire » September 2019 includes an article on immunotherapy in oncology: “Cancer immunotherapy: the next revolution in veterinary oncology? “written by Veterinary Doctor Stéphane Doliger.
Survival rates of dogs with lymphoma multiplied by 5,6
May 2019. Urodelia, a French research company focused on the development of a therapeutic cancer vaccine, and a team of Italian veterinary researchers publish promising results issued of 6 years of treatment of 300 dogs that show a survival rate compared to conventional chemotherapy that can be multiplied by 5.6 on targeted diseases.
Urodelia, AT THE HEART OF RESEARCH ON THERAPEUTIC VACCINES IN IMMUNO-ONCOLOGY
February 2019. Urodelia, a French research company focused on the development of a therapeutic vaccine in
oncology, is seeking to raise 2.5 million euros in 2019 to deploy its technology in veterinary
oncology and fund human health research. Its needs 6 million euros over 3 years.
A new therapeutic approach against dog B lymphoma
Italy, 2014. Press release in French and Italian